Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.36 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.31 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.31 |
| ▸ | TYMS | P04818 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | DAO | P14920 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6355829 | 0.89 | GABRA1 (0.39) | GABRA1GABRB2SCN8ATAAR1ALOX5 | |
| SCHEMBL6355831 | 0.87 | GABRA1 (0.38) | GABRA1GABRB2SCN8ATAAR1ALOX5 | |
| SCHEMBL7875699 | 0.82 | GABRA1 (0.61) | GABRA1GABRB2ALOX5PTGS2TYMS | |
| SCHEMBL30529905 | 0.81 | ESR1 (0.38) | SCN8ATAAR1ALOX5PTGS2PTGER4 | |
| SCHEMBL8819214 | 0.81 | TAAR1 (0.52) | SCN8ATAAR1ALOX5PTGS2KDM4E | |
| SCHEMBL27592582 | 0.79 | GABRA1 (0.45) | GABRA1GABRB2TAAR1ALOX5PTGS2 | |
| SCHEMBL30817990 | 0.78 | GABRA1 (0.39) | GABRA1GABRB2TAAR1PTGER4PTGER3 | |
| SCHEMBL17979977 | 0.78 | GABRA1 (0.39) | GABRA1GABRB2TAAR1PTGER4PTGER3 | |
| SCHEMBL6351804 | 0.77 | GABRA1 (0.41) | GABRA1GABRB2TAAR1KDM4ECYP1A2 | |
| SCHEMBL534456 | 0.76 | TAAR1 (0.50) | TAAR1CYP1A2CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2190811-B1 | RENIN INHIBITORS | MERCK CANADA INC (CA) | 2013-08-07 | — | — | EP | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-8334308-B2 | Renin inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| US-20120035214-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2012-02-09 | — | — | US | disclosed |
| EP-2413941-A1 | RENIN INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| US-20110263658-A1 | RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-10-27 | — | — | US | disclosed |
| WO-2010114978-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2010-10-07 | — | — | WO | disclosed |
| EP-2190811-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
| WO-2009023964-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263658-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | GABRA1 1386/4885GABRB2 774/4885SCN8A 4097/4885 |
| US-20120035214-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | GABRA1 2123/4885GABRB2 1370/4885SCN8A 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.